COVID-19疫苗接种后月经紊乱的全科医生咨询——基于荷兰常规医疗数据的自身对照队列研究
该研究基于荷兰两个大型代表性全科医生数据库,纳入2021年接种COVID-19疫苗的12-49岁女性631,802人,采用回顾性自身对照队列设计,以泊松回归计算发病率比(IRR)并调整SARS-CoV-2感染为时变混杂因素。结果显示,仅12-14岁年龄组在接种辉瑞/BioNTech疫苗后,闭经/月经过少/稀发月经(IRR 1.85,95%CI 1.30-2.65)和不规则/频发月经(IRR 1.33,95%CI 1.06-1.69)的全科医生咨询有所增加;其他年龄组、其他疫苗品牌及潜在风险组未见咨询频率增加。
要点
- 12-14岁女性接种辉瑞/BioNTech疫苗后,闭经/月经过少/稀发月经的全科咨询增加(IRR 1.85,95%CI 1.30-2.65)。
- 同年龄组不规则/频发月经的全科咨询亦增加(IRR 1.33,95%CI 1.06-1.69)。
- 其他年龄组、其他疫苗品牌及潜在风险组未见全科咨询频率增加。
核心结论
- 对大多数女性而言,COVID-19疫苗接种后未发现月经紊乱的全科医生咨询增加;仅12-14岁年龄组在辉瑞/BioNTech疫苗接种后特定类型月经紊乱的全科咨询增加。
研究设计与样本
- 回顾性自身对照队列研究,纳入2021年接种COVID-19疫苗的12-49岁女性,来自荷兰两个大型代表性全科医生数据库,共631,802人。
- 暴露期设定为每次COVID-19疫苗接种后最长六个月,非暴露期为暴露期之外的所有时间;采用泊松回归计算发病率比(IRR),并调整SARS-CoV-2感染为时变混杂因素。
主要发现
- 队列共纳入631,802名女性,其中18,986人(3%)在2021年因月经紊乱咨询全科医生。
- 12-14岁年龄组在COVID-19疫苗接种后,闭经/月经过少/稀发月经的IRR为1.85(95%CI 1.30-2.65),不规则/频发月经的IRR为1.33(95%CI 1.06-1.69)。
- 该年龄组接种辉瑞/BioNTech疫苗后,闭经/月经过少/稀发月经的IRR为1.87(95%CI 1.31-2.67),不规则/频发月经的IRR为1.35(95%CI 1.06-1.70)。
- 其他年龄组、其他疫苗品牌及潜在风险组未观察到全科医生咨询频率增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Several studies described that COVID-19 vaccinations can cause menstrual disorders. Our study aimed to describe whether this also resulted in more general practitioner (GP) consultations for menstrual disorders after COVID-19 vaccination, based on a large cohort study. METHODS: A retrospective self-controlled cohort study was performed including vaccinated women in 2021 aged 12-49 years from two large, representative GP databases in the Netherlands. Incidence rates and incidence rate ratio's (IRR) were calculated using Poisson regression, adjusting for SARS-CoV-2 infection as time-varying confounder. The exposed period was set at maximum six months after each COVID-19 vaccination and the non-exposed period was defined as all-time outside the exposed period. RESULTS: The cohort included 631,802 women, of which 18,986 (3 %) consulted the GP for a menstrual disorder during 2021. Increased GP consultations were observed among 12-14 year olds for amenorrhea/hypomenorrhea/oligomenorrhea (IRR: 1.85, 95 % CI: 1.30-2.65) and irregular/frequent menstruation (IRR: 1.33, 95 % CI: 1.06-1.69) after COVID-19 vaccination in general, and after Pfizer/BioNTech vaccination (IRR: 1.87, 95 % CI: 1.31-2.67 for amenorrhea/hypomenorrhea/oligomenorrhea and IRR: 1.35, 95 % CI: 1.06-1.70 for irregular/frequent menstruation). Persons from this age group were in general also vaccinated with Pfizer/BioNTech. No increase in the frequency of GP consultations were observed for older age groups, other vaccine brands, and potential risk groups. CONCLUSION: For the majority of women, no increased GP consultations for menstrual disorders was found. Solely for the youngest age group (12-14 year olds) increased GP consultations for specific types of menstrual disorders was found after Pfizer/BioNTech vaccination.
引用
- Jajou R, Lieber T, van Puijenbroek EP, et al. GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands. Vaccine. 2024. PMID: 39004527. doi:10.1016/j.vaccine.2024.07.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。